SMARTMETRIC, INC. - Form 10-Q SEC filing

SMARTMETRIC, INC. AND SUBSIDIARY

Condensed Consolidated Statements of Changes In Stockholders’ (Deficit)

(Unaudited)

	Preferred Series C				Additional Paid	Accumulated
	Stock		Common Stock		In Capital	Deficit	Total

Balance June 30, 2022	`610,000`	`610`	`647,886,336`	`647,886`	`27,546,376`	`(30,496,043)`	`(2,301,170)`

Shares issued of common stock and warrants for cash			`271,525,383`	`271,525`	`(8,295)`		`263,230`

Shares converted from Preferred C shares to common			`14,335,488`	`14,335`	`29,415`		`43,750`

Common shares issued for services			`22,750,000`	`22,750`	`4,500`		`27,250`

Common shares issued for equity funding conversions			`867,657,908`	`867,658`	`342,045`		`1,209,704`

Shares issued against liability			`153,992,825`	`153,993`	`(1,217,945)`		`(1,063,951)`

Shares issued against warrants			`244,803,545`	`244,804`	`(244,804)`		`-`

Net loss for period						`(935,396)`	`(935,396)`

Balance June 30, 2023	`610,000`	`610`	`2,222,951,485`	`2,222,951`	`26,451,292`	`(31,431,439)`	`(2,756,583)`

Shares issued of common stock and warrants for cash			`20,100,000`	`20,100`	`(6,100)`		`14,000`

Shares converted from Preferred C shares to common			`-`	`-`	`-`		`-`

Common shares issued for services			`-`	`-`	`-`		`-`

Common shares issued for equity funding conversions			`158,134,886`	`158,135`	`-`		`158,135`

Shares issued against liability			`-`	`-`	`-`		`-`

Shares issued against warrants			`-`	`-`	`-`		`-`

Net loss for period						`(170,671)`	`(170,671)`

Balance September 30, 2023	`610,000`	`610`	`2,401,186,371`	`2,401,186`	`26,445,192`	`(31,602,110)`	`(2,755,119)`

Shares issued of common stock and warrants for cash			`260,233,336`	`260,234`			`260,234`

Shares converted from Preferred C shares to common			`-`	`-`	`-`		`-`

Common shares issued for services			`-`	`-`	`-`		`-`

Common shares issued for equity funding conversions			`161,300,000`	`161,300`	`(91,598)`		`69,702`

Shares issued against liability			`-`	`-`	`-`		`-`

Shares issued against warrants			`-`	`-`	`-`		`-`

Net loss for period						`(199,968)`	`(199,968)`

Balance December 31, 2023	`610,000`	`610`	`2,822,719,707`	`2,822,719`	`26,353,594`	`(31,802,078)`	`(2,625,155)`

Shares issued of common stock and warrants for cash			`120,833,329`	`120,833`	`(84,083)`		`36,750`

Shares converted from Preferred C shares to common			`-`	`-`	`-`		`-`

Common shares issued for services			`-`	`-`	`-`		`-`

Common shares issued for equity funding conversions			`219,440,523`	`219,442`	`(223,153)`		`(3,711)`

Shares issued against liability			`-`	`-`	`-`		`-`

Shares issued against warrants			`-`	`-`	`-`

Net loss for period						`(388,595)`	`(388,595)`

Balance March 31, 2024	`610,000`	`610`	`3,162,993,559`	`3,162,994`	`26,046,358`	`(32,190,673)`	`(2,980,711)`

See notes to consolidated financial statements

SMARTMETRIC, INC. AND SUBSIDIARY
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)

NOTE 1 - ORGANIZATION AND BASIS OF PRESENTATION

SmartMetric, Inc. (the “Company” or “SmartMetric”) was incorporated in the State of Nevada on December 18, 2002. SmartMetric’s main product is a fingerprint sensor-activated credit/debit card with a finger sensor onboard the card and a built-in rechargeable battery for portable biometric identification and card activation. This card may be referred to as a biometric credit and or debit card or the SmartMetric Biometric credit card. SmartMetric has completed development of its card along with pre-mass manufacturing cards and is now in the final stages of production of its credit/debit biometric card. The release of this card is imminent.

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles for interim financial information and with the instructions to Form 10-Q and Regulation S-X. Accordingly, they do not include all the information and footnotes required by generally accepted accounting principles for complete financial statements. In the opinion of management of the Company, the accompanying unaudited financial statements contain all the adjustments (which are of a normal recurring nature) necessary for a fair presentation. Operating results for the three and nine months ended March 31, 2024 are not necessarily indicative of the results that may be expected for the year ending June 30, 2024. For further information, refer to the financial statements and the footnotes thereto contained in the Company’s Annual Report on Form 10-K for the year ended June 30, 2023, as amended, as filed with the Securities and Exchange Commission on October 19, 2023. The consolidated balance sheet as of June 30, 2023, has been derived from the audited financial statements at that date, but does not include all the information and footnotes required by US GAAP for complete financial statements.

Going Concern

As shown in the accompanying condensed consolidated financial statements the Company has sustained recurring losses of $759,234 and $1,005,910 for the nine months ended March 31, 2024 and 2023, and has an accumulated deficit of $32,190,673, and $31,431,438 at March 31, 2024 and June 30, 2023, respectively.

These conditions raise substantial doubt about the Company’s ability to continue as a going concern within one year of the date of this filing. The financial statements do not include any adjustments relating to the recoverability and classification of asset carrying amounts or the amount and classification of liabilities that might be necessary should the Company be unable to continue as a going concern. COVID-19 has had an impact on SmartMetric’s final card production. While the delays are primarily due to supply line disruption, the Company is confident that these delays will be short-lived based on advice from our manufacturing partners, manufacturing alternatives and alternative supply lines that are being put into place by the Company.

Management believes that the Company’s capital requirements will depend on many factors. These factors include product marketing and distribution. The management plans include equity sales and borrowing in order to fund the operations.

There are no assurances that the Company will be able to achieve the level of revenues adequate to generate sufficient cash flow from operations to support the Company’s working capital requirements. To the extent that funds generated are insufficient, the Company will have to raise additional working capital. No assurance can be given that additional financing will be available, or if available, will be on terms acceptable to the Company. If adequate working capital is not available, the Company may not continue its operations.

As of the end 2023, the Company has seen its electronics assembly move forward following delays in 2020, 2021 and 2022. During the span of these past three years, SmartMetric was adversely impacted in its product development of and production plans for its biometric credit card product.

Principles of Consolidation

The condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiary, SmartMetric Australia Pty. Ltd. All significant intercompany accounts and transactions have been eliminated in consolidation. SmartMetric Australia Pty Ltd., having no assets or bank accounts and no operations, has been voluntarily dissolved as a corporation.

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Use of Estimates

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. On an ongoing basis, the Company evaluates its estimates, including, but not limited to, those related to income taxes and contingencies. The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results could differ from those estimates.

Research and Development

Recent Accounting Pronouncements

The Company does not expect the adoption of recently issued accounting pronouncements to have a significant impact on the Company’s results of operations, financial position or cash flow.

Loss Per Share of Common Stock

In accordance with FASB ASC 260, “Earnings Per Share,” the basic loss per share is computed by dividing the loss attributable to common stockholders by the weighted average number of common shares outstanding during the period. Basic net loss per share excludes the dilutive effect of stock options or warrants and convertible notes. Diluted net earnings (loss) per common share is determined using the weighted-average number of common shares outstanding during the period, adjusted for the dilutive effect of common stock equivalents, consisting of shares that might be issued upon exercise of common stock options and warrants. In periods where losses are reported, the weighted-average number of common shares outstanding excludes common stock equivalents, because their inclusion would be anti-dilutive. As of March 31, 2024 and 2023, 613,935,352 and 16,935,352 dilutive shares were excluded from the calculation of diluted loss per common share, with all dilutive shares being common stock warrants at March 31, 2024 and 2023, as their effect would be anti-dilutive.

Stock-Based Compensation

The Company records stock-based compensation in accordance with ASC 718, Compensation – Stock Compensation and ASC 505-50, Equity-Based Payments to Non-Employees. All transactions in which goods or services are the consideration received for the issuance of equity instruments are accounted for based on the fair value of the consideration received or the fair value of the equity instrument issued, whichever is more reliably measurable. Equity instruments issued to employees and the cost of the services received as consideration are measured and recognized based on the fair value of the equity instruments issued and are recognized over the employees required service period, which is generally the vesting period.

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

Fair value of financial instruments

The Company measures fair value in accordance with ASC 820 - Fair Value Measurements. ASC 820 defines fair value and establishes a three-level valuation hierarchy for disclosures of fair value measurements. ASC 820 establishes a framework for measuring fair value in generally accepted accounting principles, and expands disclosures about fair value measurements. To increase consistency and comparability in fair value measurements and related disclosures, ASC 820 establishes a fair value hierarchy which prioritizes the inputs to valuation techniques used to measure fair value into three (3) broad levels. The fair value hierarchy gives the highest priority to quoted prices (unadjusted) in active markets for identical assets or liabilities and the lowest priority to unobservable inputs. The three (3) levels of fair value hierarchy defined by ASC 820 are:

Level 1 - Inputs are unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date.

Level 2 - Inputs (other than quoted market prices included in Level 1) are either directly or indirectly observable for the asset or liability through correlation with market data at the measurement date and for the duration of the instrument’s anticipated life.

Level 3 - Inputs reflect management’s best estimate of what market participants would use in pricing the asset or liability at the measurement date. Consideration is given to the risk inherent in the valuation technique and the risk inherent in the inputs to the model. Valuation of instruments includes unobservable inputs to the valuation methodology that are significant to the measurement of fair value of assets or liabilities.

As defined by ASC 820, the fair value of a financial instrument is the amount at which the instrument could be exchanged in a current transaction between willing parties, other than in a forced or liquidation sale, which was further clarified as the price that would be received to sell an asset or paid to transfer a liability (“an exit price”) in an orderly transaction between market participants at the measurement date.

The reported fair values for financial instruments that use Level 2 and Level 3 inputs to determine fair value are based on a variety of factors and assumptions. Accordingly, certain fair values may not represent actual values of the Company’s financial instruments that could have been realized as of March 31, 2024 or that will be recognized in the future, and do not include expenses that could be incurred in an actual settlement. The carrying amounts of the Company’s financial assets and liabilities, such as cash, accounts receivable, receivables from related parties, prepaid expenses and other, accounts payable, accrued liabilities, and related party and third-party notes payables approximate fair value due to their relatively short maturities. The Company’s notes payable to related parties approximate the fair value of such instrument based upon management’s best estimate of terms that would be available to the Company for similar financial arrangements at March 31, 2024.

NOTE 3 - PREPAID EXPENSES

Prepaid expenses represent the unexpired terms of various consulting agreements as well as advance rental payments. Prepaid expenses at March 31, 2024 were $4,063.

NOTE 4 - COMMITMENTS AND CONTINGENCIES

Lease Agreement

The Company’s main office is in Las Vegas, Nevada. Rent expense under all leases for the three months ended March 31, 2024 and 2023 was $1,747 and $1,694 respectively. The Company maintains only one office. This office is in Las Vegas, NV and is a month-to-month lease.

NOTE 4 - COMMITMENTS AND CONTINGENCIES (CONTINUED)

Related Party Transactions

As of March 31, 2024 and June 30, 2023, the Company has accrued the amounts of $880,142 and $769,309, respectively, as deferred Officer’s salary for the difference between the president’s annual salary and the amounts paid.

As a result of shareholder loans and deferred officer salary, the Company has accrued a balance of $348,693 and $305,949 as interest payable as of March 31, 2024 and June 30, 2023.

On September 11, 2017, we received a license to certain patents from Chaya Hendrick, our founder and CEO, related to our technologies until the expiration of the patents. As consideration, we issued Chaya Hendrick, or her assigns, (i) 200,000 shares of Series B Convertible Preferred Stock, (ii) a royalty equal to 5% of gross revenues derived from products sold related to the patents, and (iii) certain minimum required payments beginning at $50,000 and doubling each year thereafter. The Series B Preferred Stock may be converted at the election of holder on a basis for 50 common shares for each preferred share at any time or an aggregate of 10,000,000 common shares in exchange for all 200,000 shares of Series B Convertible Preferred Stock.

Our CEO maintains an employment agreement that stipulates a $190,000 annual salary. This agreement is still in effect.

Litigation

From time to time, we may be a defendant or plaintiff in various legal proceedings arising in the normal course of our business. As of the date of this Quarterly Report, there are no material pending legal or governmental proceedings relating to us or properties to which we are a party, and, to our knowledge, there are no material proceedings to which any of our directors, executive officers or affiliates are a party adverse to us or which have a material interest adverse to us.

NOTE 5 - DEBT

On April 17, 2020, we received funds under the Paycheck Protection Program (the “PPP”), a part of the CARES Act. The loan was serviced by Chase Bank, and the application for these funds required us to, in good faith, certify that the current economic uncertainty made the loan necessary to support our ongoing operations. We used the funds for payroll and related costs. The receipt of these funds, and the forgiveness of the loan attendant to these funds, was dependent on our ability to adhere to the forgiveness criteria. The loan bore interest at a rate of 0.98% per annum and had a maturity date of April 6, 2022, with the first payment being deferred until April 17, 2021. Under the terms of the PPP, certain amounts could be forgiven if they were used in accordance with the CARES Act. The Company applied for forgiveness of this loan as of October 2021, and forgiveness was granted by the Small Business Administration. Therefore, the loan is considered paid in full.

On March 5, 2020, the Company issued a $35,000 10% convertible note to GHS Investments, LLC, in relation to an equity financing agreement (see Note 6). The note was due on December 5, 2020, and is convertible at a rate of $0.0175 per share which resulted in a discount from the beneficial conversion feature totaling $5,000. As of March 31, 2023, the note had been paid in full.

NOTE 5 - DEBT (CONTINUED)

On July 23, 2021, the Company entered into a securities purchase agreement with AJB Capital Investments, LLC (“AJB”) with respect to the sale and issuance of: (i) a commitment fee in the amount of $250,000 in the form of 12,500,000 shares of the Company’s common stock (the “Commitment Fee Shares”), (ii) a promissory note in the aggregate principal amount of $300,000 (the “Note”), (iii) common stock purchase warrants to purchase up to an aggregate of 10,000,000 shares of the common stock (the “Warrants”), and (iv) 5,000 shares of the Company’s Series D Convertible Preferred Stock. The Note and Warrants were issued on July 23, 2021. The Commitment Fee Shares were issued at a value of $250,000, the Note was issued in a principal amount of $300,000 for a purchase price of $270,000, resulting in an original issue discount of $30,000; the Warrants were issued, with an initial exercise price of $0.05 per share, subject to adjustment; and 5,000 Series D Shares were issued to be converted into the shares of common stock of the Company solely in the event of default under the securities purchase agreement. The aggregate cash subscription amount received by the Company from AJB for the issuance of the Commitment Fee Shares, Note and Warrants was $253,000, due to a reduction in the $270,000 purchase price as a result of broker, legal, and transaction fees. On February 2, 2022, the Company repaid the amounts due AJB.

On January 27, 2022, the Company entered into a securities purchase agreement with Talos Victory Fund, LLC (“TVF”). The Company issued TVF a 10% promissory note in the principal amount of $250,000 (the “Note”) and a warrant (the “Warrant”) to purchase 12,500,000 shares of the Company’s common stock, $0.001 par value per share (“Common Stock”). In connection with the agreement, the Company authorized the issuance of 12,500,000 common share warrants to TVF (“Warrant Shares”).

On January 27, 2022, the Company entered into a securities purchase agreement with Firstfire Global Opportunities Fund (“Firstfire”). The Company issued Firstfire a 10% promissory note in the principal amount of $250,000 (the “Note”) and a warrant (the “Warrant”) to purchase 12,500,000 shares of the Company’s common stock, $0.001 par value per share (“Common Stock”). In connection with the agreement, the Company authorized the issuance of 12,500,000 common share warrants to Firstfire (“Warrant Shares”).

On January 27, 2022, the Company entered into a securities purchase agreement with Mast Hill Fund, LP (“Mast Hill”). The Company issued Mast Hill a 10% promissory note in the principal amount of $250,000 (the “Note”) and a warrant (the “Warrant”) to purchase 12,500,000 shares of the Company’s common stock, $0.001 par value per share (“Common Stock”). In connection with the agreement, the Company authorized the issuance of 12,500,000 common share warrants to Mast Hill (“Warrant Shares”).

On March 8, 2022, the Company entered into a securities purchase agreement with Mast Hill, in which Mast Hill shall purchase up to five million dollars ($5,000,000) of the Company’s common stock. In connection with the execution of the Agreement, on March 8, 2022, the Company issued Mast Hill five (5) common stock purchase warrants, respectively, for the purchase of (i) 500,000 shares of common stock (the “First Warrant”), (ii) 1,000,000 shares of common stock (the “Second Warrant”), (iii) 1,000,000 shares of common stock (the “Third Warrant”), (iv) 2,500,000 shares of common stock (the “Fourth Warrant”), and (v) 62,500,000 shares of the Company’s common stock (the “Fifth Warrant”) at the exercise price (as such term is defined in each of the warrants) per share then in effect.

On March 15, 2022, the Company entered into a securities purchase agreement with Mast Hill. The Company issued Mast Hill: (i) a promissory note in the aggregate principal amount of $250,000, (ii) a common stock purchase warrant to purchase up to an aggregate of 12,500,000 shares of the Company’s common stock, par value $0.001 per share, and (iii) 12,500,000 shares of common stock.

Between August 2022 and December 2022, Mast Hill Fund, L.P. converted some of its warrants into 335,467,849 common shares representing a total of $275,000.

Between August and September 2022, Talos Victory Fund, LLC converted some of its warrants into 102,918,679 common shares representing a total of $275,000.

Between August and November 2022, Firstfire Global Opportunities Fund, LLC converted some of its warrants into 190,000,000 common shares representing $275,000.

NOTE 5 - DEBT (CONTINUED)

Between October 2022 and November 2022, Blue Lake Partners, LLC converted some of its warrants into 161,297,680 common shares representing $150,375.

In January 2023, Blue Lake Partners, LLC converted some of its warrants into 66,640,000 common shares representing $66,640.

In February 2023, Mast Hill Fund LP converted debt into 77,646,846 common shares.

In April 2023, Mast Hill Fund LP converted debt into 73,113,423 common shares.

In May 2023, Mast Hill Fund LP converted debt into 18,073,976 common shares.

In June 2023, Mast Hill Fund LP converted debt into 87,300,000 common shares.

In July 2023, Mast Hill Fund LP converted its warrants into 96,800,000 common shares.

In September 2023, Mast Hill Fund LP converted its warrants into 61,334,886 common shares.

In November 2023, Mast Hill Fund LP converted debt into 64,500,000 common shares.

In September 2023, Mast Hill Fund LP converted debt into 96,800,000 common shares.

In January 2024, Mast Hill Fund LP converted debt into 103,440,523 common shares.

In February 2024, Mast Hill Fund LP converted debt into 116,000,000 common shares.

NOTE 6 - STOCKHOLDERS’ DEFICIT

Preferred Stock

Series B Convertible Preferred Stock

On December 11, 2009, the Company filed a Certificate of Designation with the State of Nevada, to designate 500,000 shares of preferred stock as Series B Convertible Preferred Stock (“Series B Convertible Preferred Stock”). Effective November 5, 2014, the number of shares designated as Series B Convertible Preferred Stock was increased to 5,000,000 shares.

The Company issued 200,000 shares of Series B Convertible Preferred Stock upon its inception in 2004.

In October 2015, the Company issued 200,000 shares of Series B Convertible Preferred Stock.

On September 11, 2017, the Company issued an additional 210,000 shares Series B Convertible Preferred Stock to its CEO, Chaya Hendrick, in consideration for the grant of exclusive rights to the licensed patent.

As of December 31, 2023, the Company has 5,000,000 shares of Series B Convertible Preferred Stock, par value $0.001, authorized, and 610,000 shares of Series B Convertible Preferred Stock issued and outstanding.

NOTE 6 - STOCKHOLDERS’ DEFICIT (CONTINUED)

Holders of the Series B Convertible Preferred Stock are entitled to receive dividends or other distributions with the holders of the common stock of the Company on an as converted basis when, as, and if declared by the directors of the Company. Holders of the Series B Convertible Preferred Stock are entitled to convert each share of the Series B Convertible Preferred Stock into fifty (50) shares of common stock. The outstanding shares of Series B Convertible Preferred Stock are entitled to vote on any matter with the holders of common stock voting together as one (1) class and shall have that number of votes (identical in every other respect to the voting rights of the holder of common stock entitled to vote at any regular or special meeting of stockholders) equal to that number of common shares which is not less than 51% of the vote required to approve any action, which Nevada law provides may or must be approved by vote or consent of the common shares or the holders of other securities entitled to vote, if any.

Upon any liquidation, dissolution or winding-up of the Company, whether voluntary or involuntary, holders of the Series B Convertible Preferred Stock are entitled to receive out of the assets, whether capital or surplus, of the Company an amount equal to the Stated Value, pro rata with the holders of the common stock.

Series C Convertible Preferred Stock

From time to time, the Company issues Series C Convertible Preferred Stock in exchange for cash. These shares are convertible into shares of the Company’s common stock at the price of $0.9090.

The number of issued and outstanding shares of Series C Convertible Preferred Stock were 17,300 and 17,300, respectively, for March 31, 2024 and June 30, 2023.

Series D Convertible Preferred Stock

On July 27, 2021 the Company designated Series D Convertible Preferred Stock (the “Series D Shares”). The Series D Shares have a stated value of $100.00 (the “Stated Value”), and carry a conversion price of the volume weighted average price (for the 20 trading days immediately prior to the conversion date). The number of shares of common stock to be issued upon any conversion shall be calculated as the quotient of (i) the product of the issued shares of the Series D Shares to be converted and the Stated Value, and (ii) the Conversion Price. The Series D Shares are not entitled to receive dividends or other distributions, and have no voting rights.

Common Stock

During the three months ended September 30, 2022, the Company issued 257,962,697 shares of common stock, of which 9,750,000 were issued from stock payable, 14,385,488 were converted from 48,125 shares of Preferred stock, 22,250,000 shares were issued for advertising and promotional services and 221,327,209 shares were issued in conjunction with securities purchase agreements for net proceeds of $291,410.

During the three months ended September 30, 2022, the Company sold zero shares of common stock for net proceeds of $0.

During the three months ended September 30, 2023, the Company sold for cash 20,100,000 shares of common stock at $0.0005 for net proceeds of $14,000.

During the three months that ended September 30, 2023, the Company issued 178,234,886 shares of common stock, of which 20,100,000 were issued for cash and 158,134,886 shares were issued in conjunction with securities purchase agreements.

During the three months ended December 31, 2023, the Company sold for cash 260,233,336 shares of common stock for net proceeds of $130,118.

During the three months that ended December 31, 2023, the Company issued 421,533,336 shares of common stock, of which 176,900,002 were issued for cash and 161,300,000 shares were issued in conjunction with securities purchase agreements and 83,333,334 shares were issued in conjunction with Regulation A.

NOTE 6 - STOCKHOLDERS’ DEFICIT (CONTINUED)

During the three months ended March 31, 2024, the Company received net proceeds of $21,380 for which 71,333,331 shares are yet to be issued.

During the three months that ended March 31, 2024, the Company issued 340,273,852 shares of common stock, of which 120,833,329 were issued for cash and 219,440,523 shares were issued in conjunction with securities purchase agreements.

Outstanding - June 30, 2023			16,935,352
Issued			597,000,000
Exercised			-
Expired			-
Outstanding - March 31, 2024			613,935,352

March 31, 2023:

Outstanding - June 30, 2022	45,997,852
Issued	-
Exercised	-
Expired	(29,062,500	)
Outstanding - March 31, 2023	16,935,352

At March 31, 2024, all 613,935,352 warrants are vested and all 613,935,352 warrants expire at various times prior to July 9, 2024.

NOTE 7 - MANDATORY REDEEMABLE CONVERTIBLE PREFERRED STOCK

Issuances of Series C Convertible Preferred Stock

On January 10, 2019, the Board of Directors of the Company adopted a resolution pursuant to the Company’s Certificate of Incorporation, as amended, providing for the designations, preferences and relative, participating, optional and other rights, and the qualifications, limitations and restrictions, of the Series C Convertible Preferred Stock.

On January 14, 2019, the Company filed a Certificate of Designations for its Series C Convertible Preferred Stock. The authorized number of Series C Convertible Preferred Stock is 1,000,000 shares, par value 0.001. The Series C Convertible Preferred Stock will, with respect to dividend rights and rights upon liquidation, winding-up or dissolution, rank: (a) senior with respect to dividends and right of liquidation with the Company’s common stock, (b) junior with respect to dividends and right of liquidation with respect to the Company’s Series B Preferred Stock, and (c) junior with respect to dividends and right of liquidation to all existing indebtedness of the Company. The Series C Convertible Preferred Stock will carry an annual ten percent (10%) cumulative dividend, compounded daily, payable solely upon redemption, liquidation or conversion. The Company will have a right, at any time in the period of 180 days from the date of the issuance, at the Company’s option, to redeem all or any portion of the Series C Preferred Stock at prices ranging from 105% to 130%, based on the passage of time.

The number of shares of Series C Convertible Preferred Stock issued and outstanding were 17,300 and 17,300, respectively, for March 31, 2024 and June 30, 2023.

NOTE 7 - MANDATORY REDEEMABLE CONVERTIBLE PREFERRED STOCK (CONTINUED)

The holders of Series C Convertible Preferred Stock shall have the right at any time during the period beginning on the date which is six (6) months following the date of their issuance, to convert all or any part of the outstanding Series C Convertible Preferred Stock into fully paid and non-assessable shares of common stock at the Variable Conversion Price. The “Variable Conversion Price” shall mean 71% multiplied by the Market Price (representing a discount rate of 29%). “Market Price” means the average of the two (2) lowest Trading Prices (which means, for any security as of any date, the closing bid price on the OTCQB, OTCQX, Pink Sheets electronic quotation system or applicable trading market (the “OTC”) as reported by a reliable reporting service (“Reporting Service”) designated by the holder (i.e. Bloomberg) for the common stock during the fifteen (15) Trading Day Period ending on the latest complete Trading Day prior to the date of conversion (both terms as defined in the Certificate of Designations).

The Series C Convertible Preferred stock is convertible after six months at 71% of the average market price of the Company’s stock based on the lowest two (2) market closes fifteen (15) days prior. Consequently, the shares were converted at different rates. The Company assessed the conversion feature and determined it was required to be bifurcated and recognized as a derivative liability. Three (3) batches of Preferred stock were subject to derivative liability valuation based on the Black Scholes Merton pricing model. As the fair value of each of the three (3) derivative and the shares issued at inception were in excess of the face amount of the Preferred stock, the Company recorded a discount in the amount of $35,000 to be amortized utilizing the effective interest method of accretion over the term of the note.

On the date which is eighteen (18) months following the Issuance Date or upon the occurrence of an Event of Default (the “Mandatory Redemption Date”), the Company shall redeem all of the shares of Series C Convertible Preferred Stock of the holder (which have not been previously redeemed or converted). Within five (5) days of the Mandatory Redemption Date, the Company shall make payment to each holder of an amount in cash equal to the total number of shares of Series C Convertible Preferred Stock held by such holder multiplied by the then current Stated Value.

All shares of mandatorily redeemable convertible preferred stock have been presented outside of permanent equity in accordance with ASC 480, Classification and Measurement of Redeemable Securities. The Company accretes the carrying value of its Series C Convertible Preferred Stock to its estimate of fair value (i.e., redemption value) at period end.

The carrying value of the Series C Convertible Preferred Stock at March 31, 2024 and June 30, 2023 was $15,728 and $15,728 net of discount, respectively. There were 0 shares of Series C Preferred Stock issued for net proceeds of $0, and 0 shares of Series C Preferred Stock converted to 0 shares of common stock for the three months ended March 31, 2024.

NOTE 8 - DERIVATIVE LIABILITIES

The conversion rates of the convertible notes and Series C Convertible Preferred Stock are convertible at a variable rate. Accordingly, when appropriate, the Company may conclude that there is an embedded derivative which would be required to be bifurcated and accounted for as a derivative liability. For this calculation, the Company elects to use the Black Scholes model to calculate the derivative liability. At March 31, 2024, there is no amount for derivative liabilities.

Level 1

Level 2

Level 3

Total

Derivative liability

NOTE 9 - INCOME TAXES

The Company provides for income taxes at the end of each interim period based on the estimated effective tax rate for the full fiscal year. Cumulative adjustments to the Company’s estimate are recorded in the interim period in which a change in the estimated annual effective rate is determined.

The Company has estimated its effective tax rate to be 0%, based primarily on losses incurred and the uncertainty of realization of the tax benefit of such losses.

Deferred income taxes are determined using the liability method for the temporary differences between the financial reporting basis and income tax basis of the Company’s assets and liabilities. Deferred income taxes are measured based on the tax rates expected to be in effect when the temporary differences are included in the Company’s tax return. Deferred tax assets and liabilities are recognized based on anticipated future tax consequences attributable to differences between financial statement carrying amounts of assets and liabilities and their respective tax bases. The Company recognizes interest and penalties related to income tax matters as a component of income tax expense.

At March 31, 2024 and 2023, deferred tax assets consist of the following:

	2024			2023
Net operating loss carryforward	$	32,190,673		$	31,478,445
Warrant issuances		-			-
Deferred officer compensation		880,142			737,642
Other		-			-
Valuation allowance		(33,070,815	)		(32,216,087	)
Deferred tax assets, net	$	-		$	-

At March 31, 2024, the Company had a net operating loss carry-forwards in the amount of approximately $32,190,673 available to offset future taxable income through 2041. These amounts may be carried forward indefinitely, subject to the 80% of taxable income limitation rule. The Company established valuation allowances equal to the full amount of the deferred tax assets due to the uncertainty of the utilization of the operating losses in future periods.

NOTE 10 - SUBSEQUENT EVENTS

In accordance with ASC 855-10, the Company has reviewed its operations subsequent to March 31, 2024 to the date these financial statements were issued. Between March 31, 2024 and May 15, 2024, other than as described in “Recent Developments” in Part I, Item 2 of this Quarterly Report, there were no subsequent events.

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

You should read the following discussion of our financial condition and results of operations in conjunction with our condensed consolidated financial statements and the related notes included elsewhere in this Quarterly Report on Form 10-Q and with our audited consolidated financial statements included in our Annual Report on Form 10-K for the year ended June 30, 2023, as filed with the Securities and Exchange Commission. In addition to our historical condensed consolidated financial information, the following discussion contains forward-looking statements that reflect our plans, estimates, and beliefs. Our actual results could differ materially from those discussed in the forward-looking statements. Factors that could cause or contribute to these differences include those discussed below and elsewhere in this Quarterly Report on Form 10-Q, particularly in Part II, Item 1A, “Risk Factors.”

Overview

SmartMetric, Inc. is a company engaged in the development and manufacture of biometric fingerprint activated credit and debit cards. SmartMetric’s founder and product inventor Chaya Hendrick, has secured issued patents covering the biometric credit and debit card fingerprint activated invention. In addition, SmartMetric holds the license to issued patents covering features of its biometric fingerprint activated cards. SmartMetric’s main product under development is a fingerprint sensor activated credit/debit card with a finger sensor and fully functional fingerprint reader embedded inside the card. The cards have a rechargeable battery allowing for portable biometric identification and card activation. These cards are herein sometimes referred to as a biometric card or the SmartMetric Biometric card.

SmartMetric has created earlier versions of its credit/debit biometric fingerprint activated credit card. The latest version, designed to be compliant with the requests of a major global payments network, is now in the final stages of development so that it can be presented to the network and various card issuing banks.

To date, we have devoted substantially all of our efforts and financial resources to the development of our biometric card. Since our inception in 2002, we have generated no revenue from product sales and have funded our operations principally through the private sales of our equity or equity-linked debt securities. We have never been profitable and, as of March 31, 2024 and June 30, 2023, we had an accumulated deficit of $32,190,673 and $31,431,438, respectively. We expect to continue to incur significant operating losses for the foreseeable future as we continue the development of our technologies and advance them to market.

Our cash and cash equivalents balance at March 31, 2024, was approximately $14,861, representing 23.7% of total assets. Based on our current expected level of operating expenditures and capital raises, we expect to be able to fund our operations through all of 2024. This period could be shortened if there are any significant increases in spending that were not anticipated or other unforeseen events.

We anticipate raising additional cash through the private or public sales of equity or debt securities to continue to fund our operations and the development of our technologies. There is no assurance that financing will be available to us when needed in order to allow us to continue our operations, or if available, on terms acceptable to us. If we do not raise sufficient funds in a timely manner, we may be forced to curtail operations, delay or stop our ongoing clinical trials, cease operations altogether, or file for bankruptcy. We currently do not have commitments for future funding from any source.

Going Concern

The condensed consolidated financial statements do not include any adjustments relating to the carrying amounts of recorded assets or the carrying amounts and classification of recorded liabilities that may be required should the Company be unable to continue as a going concern.

As shown in the accompanying consolidated financial statements, the Company has incurred recurring losses of $759,234 and $1,005,910 for the nine month period ending March 31, 2024 and 2023, respectively, and has incurred a cumulative loss of $32,190,673 and $31,431,438 as of March 31, 2024 and June 30, 2023. The Company is currently in the development stage and has spent a substantial portion of its time and efforts on the development of its technology.

There is no guarantee that the Company will be able to raise enough capital or generate revenues to sustain its operations. These conditions raise substantial doubt about the Company’s ability to continue as a going concern

beyond calendar year 2024. The Company maintains sufficient cash to continue as a going concern throughout all of calendar year 2024.

Management believes that the Company’s capital requirements will depend on many factors. These factors include the final phase of development and mass production being successful as well as product implementation and distribution.

The consolidated financial statements do not include any adjustments relating to the carrying amounts of recorded assets or the carrying amounts and classification of recorded liabilities that may be required should the Company be unable to continue as a going concern.

Recent Developments

Issuance of Commitment Shares, Notes and Warrants to Three Investors

On January 27, 2022, we entered into separate securities purchase agreements with three investors, for the sale and issuance to each investor of: (i) a promissory note in the aggregate principal amount of $250,000, (ii) a common stock purchase warrant to purchase 12,500,000 shares of the Company’s common stock, and (iii) a commitment fee in the form of 12,500,000 shares of the Company’s common stock.

Mast Hill Equity Purchase Agreement and Registration Rights Agreement to Mast Hill Fund, L.P.

On March 8, 2022, we entered into an equity purchase agreement with Mast Hill Fund, L.P. (“Mast Hill”), pursuant to which, upon the terms and subject to the conditions thereof, Mast Hill is committed to purchase, shares of our common stock at an aggregate price of up to $5,000,000 over the course of its term.

Additionally, in connection with the execution of the equity purchase agreement, the Company issued Mast Hill five (5) common stock purchase warrants, respectively, for the purchase of (i) 500,000 shares of common stock, (ii) 1,000,000 shares of common stock, (iii) 1,000,000 shares of common stock, (iv) 2,500,000 shares of common stock, and (v) 62,500,000 shares of the Company’s common stock at the Exercise Price (as such term is defined in each warrant) per share then in effect.

The Company also entered into a registration rights agreement whereby the Company shall (i) file with the United States Securities and Exchange Commission (the “SEC”) a registration statement within forty-five (45) days of the date of such agreement; and (ii) have the registration statement declared effective by the Commission within ninety (90) days after the date the registration statement is filed with the SEC (or at the earliest possible date if prior to ninety (90) calendar days from the date hereof), and any amendment declared effective by the SEC at the earliest possible date.

On September 29, 2022, the Company entered into a security purchase agreement with Mast Hill Fund, L.P. for the issuance of a promissory note in the gross amount of $306,000, for net proceeds of $291,410.

Issuance of Commitment Shares, Note, and Warrant to Mast Hill Fund, L.P.

On March 15, 2022, we entered into a securities purchase agreement with Mast Hill with respect to the sale and issuance to the Mast Hill of: (i) a promissory note in the aggregate principal amount of $250,000, (ii) a common stock purchase warrant to purchase up to an aggregate of 12,500,000 shares of the Company’s common stock, and (iii) 12,500,000 shares of common stock.

Critical Accounting Policies

We have prepared our financial statements in conformity with accounting principles generally accepted in the United States, which requires management to make significant judgments and estimates that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. We base these significant judgments and estimates on historical experience and other applicable assumptions we believe to be reasonable based upon information presently available. These estimates may change as new events occur, as additional information is obtained and as our operating environment changes. These changes have historically been minor and have been included in the financial statements as soon as they became known. Actual results could materially differ from our estimates under different assumptions, judgments or conditions.

All of the Company’s significant accounting policies are discussed in Note 2, Summary of Significant Accounting Policies, to our financial statements, included above in this Quarterly Report. We have identified the following as our significant accounting policies and estimates, which are defined as those that are reflective of significant judgments and uncertainties, are the most pervasive and important to the presentation of our financial condition and results of operations and could potentially result in materially different results under different assumptions, judgments or conditions.

We believe the following critical accounting policies reflect our more significant estimates and assumptions used in the preparation of our financial statements:

Development Costs

Research and development costs are charged to expense as incurred. Our research and development expenses consist primarily of expenditures for electronics design and engineering, software design and engineering, component sourcing, component engineering, manufacturing, product trials, compensation and consulting costs. Due to the small size of the Company’s research & development staff as well as the lack of any long term research and development-related contracts, we do not believe that the use of this critical accounting estimate will have a material impact on the results of financial operations.

Results of Operations

Comparison of the Three Months Ended March 31, 2024 and 2023

Our results of operations have varied significantly from year to year and quarter to quarter and may vary significantly in the future. We did not have revenue for the three months ending March 31, 2024 and 2023. Net loss for the three months ended March 31, 2024, and net income (attributable to common shareholders) for March 31, 2023 were $388,595 and $310,740 respectively, resulting from the operational activities described below.

Operating Expenses

Operating expense totaled $133,122 and $187,023 during the three months ended March 31, 2024 and 2023, respectively. The decrease in operating expenses is the result of lower consulting expenses and legal expenses.

	Quarter Ended March 31,				Change in 2024 Versus 2023
	2024		2023		$		%
Operating expense
Officer salary	$	47,500	$	47,500	$	-0-		-0-	%
Advertising costs		40,756		39,240		1,516		3.9	%
Legal & professional fees		4,037		20,816		(16,779)		(80.6	)%
Research and development		9,000		31,807		(22,807)		(71.7	)%
Amortization expense		663		352		(311)		(88.4)	%
General and administrative		31,166		47,308		(16,142)		(34.1)	%
Total operating expense	$	133,122	$	187,023	$	(53,901)		(28.8)	%

Research and Development

Research and development expenses totaled $9,000 and $31,807 for the three months ended March 31, 2024 and 2023, respectively. The decrease of $22,807, or 71.7%, in 2024 compared to 2023 was primarily attributable to decreased engineering expenses. Our research and development expenses consist primarily of expenditures related to engineering.

General and Administrative

General and administrative expenses totaled $31,166 and $47,308 for the three months ended March 31, 2024 and 2023, respectively. The decrease of $16,142, in 2024 compared to 2023 was primarily the result of an decrease in consulting and legal expenses. Our general and administrative expenses consist primarily of expenditures related to employee compensation, legal, accounting and tax, other professional services, and general operating expenses.

Other Expense

Other income (expense) totaled ($255,473) and ($123,717) for the three months ended March 31, 2024 and 2022, respectively.

	Quarter Ended March 31,				Change in 2024 Versus 2023
	2024		2023		$		%
Gain (loss) on change in derivatives		-0-		-0-	$	-0-		(-	)
Gain (loss) on conversions		(240,387)		(105,638)		(134,749)		(127.6	)%
Gain (loss) on derivative liabilities		-0-		-0-		-0-		(-	)
Gain on PPP loan forgiveness		-0-		-0-		-0-		(-	)
Interest Expense		(15,086)		(18,079)		2,993		16.6	%
Other income (expense)		-0-		-0-		-0-		(-)
Total other (income) expense	$	(255,473)	$	(123,717)	$	(131,756)		(106.5)	%

Interest income (expense)

We had net interest expense of ($15,086) in the three months ended March 31, 2024, compared to ($18,079) net interest expense for the three months ended March 31, 2023. The decrease of $2,993 was attributable to lower interest on deferred officer salary.

Gain (loss) on conversion

We had a gain (loss) on conversion of ($240,387) in the three months ended March 31, 2024, compared to a ($105,638) gain (loss) on conversion for the three months ended March 31, 2023.

Gain on PPP loan forgiveness

We recognized $0 on the forgiveness of a PPP loan during the three months ended March 31, 2024, compared to $0 for the three months ended March 31, 2023.

Liquidity and Capital Resources

We have incurred losses since our inception as a result of significant expenditures for operations and research and development and the lack of any revenue. We have an accumulated deficit of $32,190,673 as of March 31, 2024, and anticipate that we will continue to incur additional losses for the foreseeable future. Through March 31, 2024, we have funded our operations through the private sale of our equity securities and exercises of options and warrants, resulting in gross proceeds of approximately $29.3 million from inception through March 31, 2024.

	Nine Months Ended March 31,					Change in 2024 Versus 2023
	2024			2023		$		%
Cash at beginning of period	$	20,012		$	126,791	$	(106,779)		(84.2	)%
Net cash used in operating activities		(255,722	)		(673,837)		418,115		62.0	%
Net cash used in investing activities		-0-			-0-		-0-		0	%
Net cash provided by financing activities		250,571			582,568		(331,997)		(57.0	)%
Cash at end of period	$	14,861		$	35,522	$	(20,661)		(58.2	)%

Net Cash Used in Operating Activities

Net cash used in operating activities was $255,722 and $673,837 for the nine months ended March 31, 2024 and 2023, respectively. The decrease of $418,115 in cash used during 2024 compared to 2023 was primarily attributable to a decrease in proceeds from private placements, loss from conversion of notes to shares, offset by change in fair value of derivative liability.

Net Cash Used in Investing Activities

Cash used in investing activities was $0 and $0 for the six months ended March 31, 2024 and 2023, respectively.

Net Cash Provided by Financing Activities

During the nine months ended March 31, 2024, net cash provided by financing activities was $250,571, compared to $582,568 for the nine months ended March 31, 2024. The decrease of $331,997 was due to lower sales of the Company’s securities in private placements. We continue to seek funding through private placement sales of equity to fund our continued operations, sales and marketing and ongoing research and development programs.

Equity Financing Agreement

Issuance of Commitment Shares, Notes and Warrants to Three Investors

Mast Hill Equity Purchase Agreement and Registration Rights Agreement to Mast Hill Fund, L.P.

Issuance of Commitment Shares, Note, and Warrant to Mast Hill Fund, L.P.

On March 15, 2022, we entered into a securities purchase agreement with Mast Hill with respect to the sale and issuance to Mast Hill of: (i) a promissory note in the aggregate principal amount of $250,000, (ii) a common stock purchase warrant to purchase up to an aggregate of 12,500,000 shares of the Company’s common stock, and (iii) 12,500,000 shares of common stock.

On September 29, 2022, the Company entered into a security purchase agreement with Mast Hill for the issuance of a promissory note in the gross amount of $306,000, for net proceeds of $291,410.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

We are not required to provide the information required by this item as we are considered a smaller reporting company.

ITEM 4. CONTROLS AND PROCEDURES

Disclosure controls are procedures that are designed with the objective of ensuring that information required to be disclosed in our reports filed under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), such as this Form 10-Q, is recorded, processed, summarized and reported within the time periods specified in the SEC’s

rules and forms. Disclosure controls are also designed with the objective of ensuring that such information is accumulated and communicated to our management, including the Principal Executive Officer and Principal Financial Officer, as appropriate, to allow timely decisions regarding required disclosure. Internal controls are procedures which are designed with the objective of providing reasonable assurance that (1) our transactions are properly authorized, recorded and reported; and (2) our assets are safeguarded against unauthorized or improper use, to permit the preparation of our condensed consolidated financial statements in conformity with GAAP. In designing and evaluating the disclosure controls and procedures, our management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives.

In connection with the preparation of this Quarterly report on Form 10-Q for the quarter ended March 31, 2024, our principal executive officer and principal financial officer have concluded that our disclosure controls and procedures were not effective (as defined in Rules 13a-15(e) and 15d-15(e) of the Exchange Act) are not effective to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the U.S. Securities and Exchange Commission’s rules and forms and to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is accumulated and communicated to our management, including our Chief Executive Officer, as appropriate to allow timely decisions regarding required disclosure.

Limitations on Controls

Management does not expect that the Company’s disclosure controls and procedures or the Company’s internal control over financial reporting will prevent or detect all error and fraud. Any control system, no matter how well designed and operated, is based upon certain assumptions and can provide only reasonable, not absolute, assurance that its objectives will be met. Further, no evaluation of controls can provide absolute assurance that misstatements due to error or fraud will not occur or that all control issues and instances of fraud, if any, within the Company have been detected.

Due to our size and nature, segregation of all conflicting duties may not always be possible and may not be economically feasible. However, to the extent possible, the initiation of transactions, the custody of assets and the recording of transactions are being performed by separate individuals. Management evaluated the impact of our failure to have segregation of duties in all of our financially significant processes and have concluded that this control deficiency represented a material weakness. We plan to remediate this weakness over the next 6 months.

Consequently, we believe that our condensed consolidated financial statements contained in this Form 10-Q fairly present our financial position, results of operations and cash flows for the periods covered thereby in all material respects.

Changes in Internal Controls

During the three and nine months ended March 31, 2024, there have been no changes in our internal control over financial reporting that have materially affected or are reasonably likely to materially affect our internal controls over financial reporting.

PART II. OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

From time to time, we may be a defendant or plaintiff in various legal proceedings arising in the normal course of our business. We know of no material, active, pending or threatened proceeding against us or our subsidiaries, nor are we, or any subsidiary, involved as a plaintiff or defendant in any material proceeding or pending litigation.

ITEM 1A. RISK FACTORS

In addition to the other information set forth in this report, you should carefully consider the risk factors discussed in Part I, Item 1A in our Annual Report on Form 10-K for the year ended June 30, 2023, as amended, filed with the Commission on October 19, 2023, and our subsequent filings with the Commission, which could materially affect our business, financial condition or future results. These cautionary statements are to be used as a reference in connection with any forward-looking statements. The factors, risks and uncertainties identified in these cautionary statements are in addition to those contained in any other cautionary statements, written or oral, which may be made

or otherwise addressed in connection with a forward-looking statement or contained in any of our subsequent filings with the Commission.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

The following information is given with regard to unregistered securities sold during the three months ended March 31, 2024, and not previously reported on a Current Report on Form 8-K. The following securities were issued in private offerings pursuant to the exemption from registration contained in the Securities Act of 1933, as amended (the “Securities Act”) and the rules promulgated thereunder in reliance on Section 4(a)(2) thereof and Regulation D and Regulation S promulgated thereunder, relating to offers of securities by an issuer not involving any public offering.

During the three months ended September 30, 2023, the Company sold 20,100,000 shares of common stock for cash proceeds of $14,000, 199,000,000 A Warrants, 199,000,000 B Warrants and 199,000,000 C Warrants. All warrants expire at various times between July 2025 and September 2025.

During the three months that ended September 30, 2023, the Company issued 178,234,886 shares of common stock.

20,100,000 of these shares were issued for cash received in prior quarters from private placement investors and were charged against stock liability.

158,134,886 of these shares were issued in conjunction with securities purchase agreements with Mast Hill Fund, LP.

During the three months ended December 31, 2023, the Company sold for cash 260,233,336 shares of common stock at $0.0005 for net proceeds of $130,118.

During the three months ended March 31, 2024, the Company has received net proceeds of $21,380 for which 71,333,331 shares are yet to be issued.

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

Not Applicable.

ITEM 4. MINE SAFETY DISCLOSURES

Not Applicable.

ITEM 5. OTHER INFORMATION

None.

ITEM 6. EXHIBITS

INDEX TO EXHIBITS

		Filed or Furnished	Incorporated by Reference
Exhibit No.	Description	Herewith	Form	Exhibit No.	Filing Date
3.01	Articles of Incorporation of SmartMetric, Inc. 12/18/02		SB-2	3.1	09/03/04

3.02	Amendment to Articles of Incorporation dated 12/11/09		8-K	3.1	12/18/09

3.03	Amendment to Articles of Incorporation dated 06/08/16		10-K	3.5	09/28/16

3.04	Amendment to Articles of Incorporation dated 10/17/19		8-K	3.1	12/11/19

3.05	Amendment to Articles of Incorporation dated 05/24/21		8-K	3.1	05/28/21

3.06	Series B Preferred Stock Certificate of Designations dated 12/11/09		8-K	3.2	12/18/09

3.07	Amendment to Series B Preferred Stock Certificate of Designation dated 11/05/14		10-Q	3.1	11/14/14

3.08	Amendment to Series B Preferred Stock Certificate of Designation dated 06/08/16		10-K	3.4	09/28/16

3.09	Series C Preferred Stock Certificate of Designations dated 01/14/19		8-K	3.1	01/18/19

3.10	Series D Preferred Stock Certificate of Designations dated 07/27/21		8-K	3.1	07/29/21

3.11	Amended and Restated Bylaws of SmartMetric		8-K	3.1	04/26/16

3.12	Amended and Restated Bylaws of SmartMetric		8-K	3.1	04/29/21

4.1	Promissory Note in the principal amount of $300,000 dated 07/23/21		8-K	4.1	07/29/21

4.2	Common Stock Purchase Warrant dated 07/23/21		8-K	4.2	07/29/21

4.3	Form of Promissory Note dated 01/27/22		8-K	4.1	02/03/22

4.4	Form of Common Stock Purchase Warrant dated 01/27/22		8-K	4.2	02/03/22


4.5	Form of Common Stock Purchase Warrant dated 03/08/22		S-1	4.13	05/23/22

4.6	Promissory Note in the principal amount of $250,000 dated 03/15/22		8-K	4.1	03/21/22

4.7	Common Stock Purchase Warrant dated 03/15/22		8-K	4.2	03/21/22

10.1	Securities Purchase Agreement dated 07/23/21		8-K	10.1	07/29/21

10.2	Form of Securities Purchase Agreement dated 01/27/22		8-K	10.1	02/03/22

10.3	Equity Purchase Agreement dated 03/08/22		S-1	10.19	05/23/22

10.4	Registration Rights Agreement dated 03/08/22		S-1	10.20	05/23/22

10.5	Securities Purchase Agreement dated 03/15/22		8-K	10.1	03/21/22

10.6**	Waiver and Consent Agreement dated 11/03/21		10-Q	10.2	02/15/22

10.7	Employment Agreement with Chaya Hendrick dated 05/13/22		S-1	10.7	05/23/22

31.1	Certification by the Principal Executive Officer of Registrant pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 (Rule 13a-14(a) or Rule 15d-14(a)).	X

31.2	Certification by the Principal Financial Officer of Registrant pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 (Rule 13a-14(a) or Rule 15d-14(a)).	X

32.1*	Certification by the Principal Executive Officer pursuant to 18 U.S.C. 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002*.	X

32.2*	Certification by the Principal Financial Officer pursuant to 18 U.S.C. 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002*.	X

101.INS	XBRL Instance Document	X

101.SCH	XBRL Taxonomy Extension Schema Document	X

101.CAL	XBRL Taxonomy Extension Calculation Linkbase Document	X

101.DEF	XBRL Taxonomy Extension Definition Linkbase Document	X

101.LAB	XBRL Taxonomy Extension Label Linkbase Document	X


101.PRE	XBRL Taxonomy Extension Presentation Linkbase Document	X

104	Cover Page Interactive Data File (formatted as inline XBRL with applicable taxonomy extension information contained in Exhibits 101).

*	In accordance with SEC Release 33-8238, Exhibits 32.1 and 32.2 are being furnished and not filed.
**	Certain schedules, exhibits and similar attachments have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The Company hereby undertakes to furnish copies of such omitted materials supplementally upon request by the SEC.

SIGNATURES

In accordance with the requirements of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	SMARTMETRIC, INC.

Dated: June 10, 2024	By:	/s/ Chaya Hendrick
		Chaya Hendrick,
		President, Chief Executive Officer and Chairman
		(Principal Executive Officer)

Dated: June 10, 2024	By:	/s/ Jay Needelman
		Jay Needelman,
		Chief Financial Officer
		(Principal Financial Officer)

內華達		05-0543557
（註冊或組織的）提起訴訟的州或其他司法管轄區（如適用）組建國的駐地		（美國國內國稅局僱主唯一識別號碼）

3960 Howard Hughes Parkway, Suite 500, 拉斯維加斯市, 內華達州		89169
主執行辦公室地址		郵政編碼

每一類的名稱		交易標誌		在其上註冊的交易所的名稱
無數據		無數據		無數據

大型加速報告人	☐	加速文件提交人	☐
非加速文件提交人	☒	較小的報告公司	☒
新興成長公司	☒

第I部分	財務信息
項目1。	基本報表
	截至2024年3月31日的合併簡明資產負債表（未經審計）和2023年6月30日	1
	截至2024年3月31日止三個和九個月的合併簡明損益表（未經審計）和2023年	2
	截至2024年3月31日止三個和九個月的合併簡明股東赤字表（未經審計）和2023年	3
	2024年3月31日截至九個月的簡明綜合現金流量表和2023年（未經審計）	4
	未經審計的簡明合併財務報表註釋	5
項目2。	分銷計劃	15
項目3。	市場風險的定量和定性披露	19
項目4。	控制和程序	19

第II部分	其他信息
項目1。	法律訴訟	20
項目1A。	風險因素	20
項目2。	未註冊的股票股權銷售和籌款用途	21
項目3。	對優先證券的違約	21
項目4。	礦山安全披露	21
項目5。	其他信息	21
項目6。	展示資料	22

	簽名	24

	March 31,	June 30,
	2024	2023
Assets
Current assets:
Cash	`$14,861`	`$20,012`
Payroll tax overpayment	`4,270`	`-`
Prepaid expenses and other current assets	`4,063`	`8,667`

Total current assets	`23,194`	`28,679`
Non-current assets
Patent costs (net of amortization)	`36,718`	`33,750`
Due from SBT	`1,750`	`-`

Total assets	`$61,662`	`$62,429`

Liabilities and Stockholders' Deficit

Current liabilities:
Accounts payable and accrued expenses	`$1,364,899`	`$1,233,488`
Liability for stock to be issued	`21,400`	`3,080`
Deferred Officer's salary	`880,142`	`769,309`
Related party interest payable	`348,693`	`305,949`
Dividends payable	`1,858`	`1,858`
Due to shareholders	`52,927`	`52,927`
Convertible note payable, net of discount	`293,790`	`400,660`
Convertible interest payable	`-`	`22,200`
Shareholder loan	`62,936`	`13,814`

Total current liabilities	`3,026,645`	`2,803,285`
Total Liabilities	`3,026,645`	`2,803,285`

Series D convertible preferred stock stated value $1.00 (See note 6)	`-`	`-`
Commitments and contingencies (See note 6)
Series C mandatory redeemable convertible preferred stock, net of discount, authorized 1,000,000 shares, 17,300 and 17,300 shares issued and outstanding, respectively	`15,728`	`15,728`
Stockholders' deficit:
Class B Preferred stock, $0.001 par value; 5,000,000 shares authorized, 610,000 and 610,000 shares issued and outstanding	`610`	`610`
Class A Preferred stock, $0.001 par value; 50,000,000 shares authorized 0 and 0 shares issued and outstanding	`-`	`-`
Common stock, $0.001 par value; 1,200,000,000,000 shares authorized, 3,162,993,559 and 2,222,951,485 shares issued and outstanding , respectively	`3,162,994`	`2,222,952`
Additional paid-in capital	`26,046,358`	`26,451,292`
Accumulated deficit	`(32,190,673)`	`(31,431,438)`

Total stockholders' deficit	`(2,980,711)`	`(2,756,583)`

Total liabilities and stockholders' deficit	`$61,662`	`$62,429`

		Nine Months	Nine Months	Three Months	Three Months
		Ended	Ended	Ended	Ended
		March 31,	March 31,	March 31,	March 31,
		2024	2023	2024	2023

Revenues		`$-`	`$-`	`$-`	`$-`

Expenses:
	Officer's salary	`142,500`	`142,500`	`47,500`	`47,500`
	Advertising costs	`131,244`	`155,952`	`40,756`	`39,240`
	Legal and professional fees	`31,237`	`119,236`	`4,037`	`20,816`
	General and administrative expenses	`126,152`	`58,032`	`31,166`	`47,308`
	Research and development	`42,767`	`104,807`	`9,000`	`31,807`
	Amortization	`1,888`	`584`	`663`	`352`

	Total operating expenses	`475,788`	`581,111`	`133,122`	`187,023`
					`-`
	Loss from operations before income taxes	`(475,788)`	`(581,111)`	`(133,122)`	`(187,023)`
	Interest & Financing Expense	`(43,059)`	`(44,035)`	`(15,086)`	`(18,079)`
	Gain on PPP loan forgiveness	`-`	`20,832`	`-`
	Gain (loss) on conversions	`(240,387)`	`(389,842)`	`(240,387)`	`(105,638)`
	Other income (expenses)	`-`	`(11,754)`	`-`
	Net loss	`(759,234)`	`(1,005,910)`	`(388,595)`	`(310,740)`
	Preferred stock dividends		`-`		`-`
	Net loss available for common stockholders	`$(759,234)`	`$(1,005,910)`	`$(388,595)`	`$(310,740)`

	Net loss per share, basic and diluted	`$(0.00)`	`$(0.00)`	`$(0.00)`	`$(0.00)`

	Weighted average number of common
	shares outstanding, basic and diluted	`2,576,273,509`	`1,200,665,574`	`38,326,590`	`1,608,311,958`